2023

1. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study

   Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 6, pp. 263-271